.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
US Department of Justice
Mallinckrodt
Fish and Richardson
Johnson and Johnson
Cantor Fitzgerald
Medtronic
Argus Health
Deloitte
Teva

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,791,153

« Back to Dashboard

Which drugs does patent 8,791,153 protect, and when does it expire?


Patent 8,791,153 protects SKLICE and is included in one NDA.

This patent has twenty-four patent family members in twelve countries.

Summary for Patent: 8,791,153

Title:Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice
Abstract: An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, non-ionic surfactants, humectants, a silicone compound, and water. Also disclosed are methods of using the topical formulations disclosed within this specification to treat either a susceptible or treatment-resistant strain of lice, as well as uses in the manufacture of a medicament for treating or preventing a lice infestation from a susceptible or treatment-resistant strain in a human patient.
Inventor(s): Spring; Nicholas (Jenkintown, PA), Gwozdz; Garry T (Bethlehem, PA)
Assignee: Sanofi-Topaz, Inc. (Wilmington, DE)
Application Number:11/871,660
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Arbor Pharms Llc
SKLICE
ivermectin
LOTION;TOPICAL202736-001Feb 7, 2012RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,791,153

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,927,595Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,791,153

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office2091325► Subscribe
Canada2666365► Subscribe
Canada2686336► Subscribe
European Patent Office2155190► Subscribe
European Patent Office2348832► Subscribe
European Patent Office2653160► Subscribe
Hong Kong1133991► Subscribe
Israel212472► Subscribe
Japan2012507545► Subscribe
Japan5694944► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Federal Trade Commission
Harvard Business School
Cipla
Citi
UBS
Farmers Insurance
Merck
Dow
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot